Workflow
和邦生物(603077) - 2024 Q2 - 季度业绩预告
HBCHBC(SH:603077)2024-07-09 08:32

Financial Performance - The company expects a net profit attributable to shareholders for the first half of 2024 to be between 190 million and 228 million yuan, a decrease of 388.53 million to 426.53 million yuan compared to the same period last year, representing a decline of 63.02% to 69.18%[2]. - The expected net profit attributable to shareholders after deducting non-recurring gains and losses for the first half of 2024 is projected to be between 185 million and 223 million yuan, a decrease of 369.88 million to 407.88 million yuan year-on-year, reflecting a decline of 62.39% to 68.80%[2]. - In the first half of 2023, the total profit was 728.84 million yuan, with a net profit attributable to shareholders of 616.53 million yuan, and a net profit of 592.88 million yuan after deducting non-recurring gains and losses[4]. Operational Challenges - The significant decline in net profit is primarily due to the impact of macroeconomic and market changes, leading to a year-on-year decrease in market prices of some products[5]. Future Outlook - The company reported a notable improvement in operational performance in the second quarter, with substantial growth in revenue and net profit compared to the first quarter[5]. - For the second half of 2024, the company plans to implement various cost-reduction and efficiency-enhancement measures to improve market competitiveness and market share[5]. Financial Reporting - The financial data provided in the announcement is preliminary and has not been audited by registered accountants, with final figures to be disclosed in the official half-year report[6].